Korea Moving To Sue 104 Drug Firms, Including Some MNCs, For Selling Substandard Generics
This article was originally published in PharmAsia News
Executive Summary
Bioequivalence tests are conducted to compare generic versions of medicines with the originals to ascertain whether or not they are equal. These tests are especially important in South Korea, where generic drugs are the main profit drivers for many local pharmaceutical producers.
You may also be interested in...
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
GSK Expands In Korea With Purchase Of 9.9 Percent Equity Stake In Dong-A Pharma
SEOUL - GlaxoSmithKline is paying KRW142.9 billion ($128.7 million) to acquire a 9.9 percent stake in South Korea's leading Dong-A pharmaceutical and OTC company. The strategic alliance should help GSK gain market share in the rapidly growing Korean pharmaceutical market
Generics of Complex Drugs Must Pass Korea FDA's Bioequivalence Test; Another Positive Development for MNCs
SEOUL - Korea's Food and Drug Administration will soon require medicines made by Korean generic drug makers to pass the agency's bioequivalence test when producing copies of branded originals with more than two active ingredients, also known as complex drugs